表纸
市场调查报告书

自体免疫相关的联盟条件与契约

Global Autoimmune Partnering 2014-2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 325528
出版日期 内容资讯 英文 650+ Pages
商品交期: 最快1-2个工作天内
价格
自体免疫相关的联盟条件与契约 Global Autoimmune Partnering 2014-2020: Deal trends, players and financials
出版日期: 2020年10月01日内容资讯: 英文 650+ Pages
简介

本报告提供自体免疫相关的联盟条件与相关契约相关调查分析、联盟交易趋势、平均交易条件、联盟契约结构、联盟契约文件、交易量 (各金额) 、最积极的契约企业等相关的系统性资讯。

第1章 简介

第2章 自体免疫相关的契约动向

  • 简介
  • 自体免疫相关的联盟的转变
  • 大型制药企业的自体免疫相关的契约活动
  • 大生物企业的自体免疫相关的契约活动
  • 自体免疫相关的联盟最积极的企业
  • 自体免疫相关的联盟:各交易类型
  • 自体免疫相关的联盟:各产品部门
  • 自体免疫相关的联盟:各开发阶段
  • 自体免疫相关的联盟:各技术类型
  • 自体免疫相关的联盟:各癌症适应症
  • 自体免疫相关的平均交易条件

第3章 自体免疫相关的主要交易

  • 简介
  • 自体免疫相关的主要交易:各金额

第4章 大型制药企业的自体免疫相关的交易

  • 简介
  • 联盟契约的有效利用方法
  • 联盟企业简介

第5章 大生物企业的自体免疫相关的交易

  • 简介
  • 联盟契约的有效利用方法
  • 联盟企业简介

第6章 自体免疫相关的联盟契约名录

  • 简介
  • 各交易类型
  • 各开发阶段
  • 各技术类型

第7章 自体免疫相关的契约:各适应症

  • 简介
  • 交易:各适应症

第8章 联盟资源中心

  • 线上联盟
  • 联盟活动
  • 契约相关相关资料

关于Wildwood Ventures

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2228

The Global Autoimmune Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Autoimmune partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Autoimmune partnering agreement structure

Autoimmune partnering contract documents

Top Autoimmune deals by value

Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

  • Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Cronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
  • The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
  • The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.
  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
  • Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
  • Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Benefits

Global Autoimmune Partnering 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Autoimmune deal trends since 2014
  • Access Autoimmune deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Autoimmune partner companies
  • Comprehensive access to over 850 links to actual Autoimmune deals entered into by the world's biopharma companies
  • Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Autoimmune opportunities
  • Uncover companies actively partnering Autoimmune opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking

  • 2.1. Introduction
  • 2.2. Autoimmune partnering over the years
  • 2.3. Autoimmune partnering by deal type
  • 2.4. Autoimmune partnering by industry sector
  • 2.5. Autoimmune partnering by stage of development
  • 2.6. Autoimmune partnering by technology type
  • 2.7. Autoimmune partnering by therapeutic indication

Chapter 3 -Financial deal terms for Autoimmune partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Autoimmune partnering
  • 3.3. Autoimmune partnering headline values
  • 3.4. Autoimmune deal upfront payments
  • 3.5. Autoimmune deal milestone payments
  • 3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Autoimmune partnering
  • 4.3. List of most active dealmakers in Autoimmune
  • 4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory

  • 5.1. Introduction
  • 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Autoimmune therapeutic target

Appendices

  • Appendix 1 - Directory of Autoimmune deals by company A-Z 2014 to 2020
  • Appendix 2 - Directory of Autoimmune deals by deal type 2014 to 2020
  • Appendix 3 - Directory of Autoimmune deals by stage of development 2014 to 2020
  • Appendix 4 - Directory of Autoimmune deals by technology type 2014 to 2020
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Autoimmune partnering since 2014
  • Figure 2: Autoimmune partnering by deal type since 2014
  • Figure 3: Autoimmune partnering by industry sector since 2014
  • Figure 4: Autoimmune partnering by stage of development since 2014
  • Figure 5: Autoimmune partnering by technology type since 2014
  • Figure 6: Autoimmune partnering by indication since 2014
  • Figure 7: Autoimmune deals with a headline value
  • Figure 8: Autoimmune deals with upfront payment values
  • Figure 9: Autoimmune deals with milestone payment
  • Figure 10: Autoimmune deals with royalty rates
  • Figure 11: Active Autoimmune dealmaking activity- 2014 to 2020
  • Figure 12: Top Autoimmune deals by value since 2014